Monensin Solution (1,000X)

Pricing & Availability
Regulatory Status
Ave. Rating
Submit a Review
Product Citations
Cat # Size Price Quantity Check Availability Save
420701 1 mL £35
Check Availability

Need larger quantities of this item?
Request Bulk Quote

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical Data Sheet (pdf)

Product Details

Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
2.0 mM
Storage & Handling
Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.

ICFC - Quality tested

Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References

(PubMed link indicates BioLegend citation)
  1. Smeltz RB. 2007. J. Immunol. 178:4786.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Durkin ET,et al. 2008. Blood 10:1182.PubMed
  4. Durkin ET, et al. 2008. Blood 112:5245. PubMed
  5. Liu XS, et al. 2009. J. Immunol. 183:51. PubMed
  6. Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed
  7. Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed
  8. Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed
  9. Wood MW, et al. 2011. Infect Immun. 79:708. PubMed
  10. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  11. Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed
  12. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  13. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  14. Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations
  1. Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed
  2. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  3. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  4. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  5. Bunse C, et al. 2013. PLoS One. 8:77925. PubMed
  6. Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed
  7. Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed
  8. Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed
  9. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  10. Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed
  11. Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed
  12. Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed
  13. Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed
  14. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  15. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed
  16. Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed
  17. Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed
  18. Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed
  19. Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed
  20. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed
  21. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  22. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  23. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  24. Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed
  25. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  26. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  27. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  28. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  29. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  30. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  31. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  32. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  33. Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed
  34. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  35. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  36. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  37. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  38. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  39. Durkin E, et al. 2008. Blood. 112:5245. PubMed
  40. Liu X, et al. 2009. J Immunol. 183:51:00. PubMed
  41. Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed
  42. Yang M, et al. 2010. J Immunol. 184:3321. PubMed
  43. Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed
  44. Wood M, et al. 2011. Infect Immun. 79:708. PubMed
  45. Munk R, et al. 2011. PLoS One. 6:e18553. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.


*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.


BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account